Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates

Relay Therapeutics (RLAY) reported a narrower-than-expected quarterly loss of $0.41 per share, beating the Zacks consensus estimate of a $0.49 loss, and posted revenues of $0.68 million, surpassing estimates by 35.40% from zero revenue a year ago. This marks the fourth consecutive quarter RLAY has exceeded EPS expectations; however, its shares have underperformed the S&P 500 year-to-date, declining 14.3%. The company holds a Zacks Rank #3 (Hold), with future stock performance largely dependent on management's commentary during the earnings call.

Analysis

Relay Therapeutics (RLAY) delivered a significant operational beat for the quarter ended June 2025, reporting a narrower-than-expected loss of $0.41 per share against a consensus estimate of a $0.49 loss, marking a 16.33% positive surprise. This result is a substantial improvement from the $0.69 per share loss recorded a year ago and represents the fourth consecutive quarter the company has surpassed EPS estimates. Furthermore, the company generated revenues of $0.68 million, which not only beat the consensus forecast by 35.40% but also compares favorably to zero revenues in the prior-year period. Despite this pattern of positive earnings surprises, the company's stock has materially underperformed the market, declining 14.3% year-to-date while the S&P 500 gained 7.9%. The prevailing sentiment is cautious, as reflected by the Zacks Rank #3 (Hold), which suggests the stock is expected to perform in line with the market. Future price action is highly dependent on management's forward-looking commentary and any subsequent revisions to earnings estimates for the coming quarters.

Key Decisions for Investors

• Investors should prioritize monitoring management's guidance from the earnings call, as this commentary will be the primary catalyst for near-term estimate revisions and stock performance.
• It is prudent to weigh the company's consistent operational outperformance, including four consecutive EPS beats and new revenue generation, against its significant year-to-date stock underperformance of -14.3%.
• Given the neutral Zacks Rank #3 (Hold) and mixed pre-earnings estimate trends, investors should watch for any post-release changes to consensus estimates as a key indicator of a potential shift in the stock's trajectory.